Skip to Content

Transderm-Scop Side Effects

Generic Name: scopolamine

Note: This page contains side effects data for the generic drug scopolamine. It is possible that some of the dosage forms included below may not apply to the brand name Transderm-Scop.

For the Consumer

Applies to scopolamine: transdermal patch extended release

As well as its needed effects, scopolamine (the active ingredient contained in Transderm-Scop) may cause unwanted side effects that require medical attention.

Major Side Effects

If any of the following side effects occur while taking scopolamine, check with your doctor immediately:

Incidence not known:
  • Blurred vision
  • chest pain or discomfort
  • difficulty with urinating
  • dilation of the pupils
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
  • eye pain
  • flushing or redness of the skin
  • mood or mental changes
  • muscle weakness
  • nausea or vomiting
  • rash
  • redness of the white part of the eyes
  • restlessness
  • seeing, hearing, or feeling things that are not there
  • shortness of breath
  • slow or irregular heartbeat
  • sweating
  • unusual tiredness
  • unusually warm skin

If any of the following symptoms of overdose occur while taking scopolamine, get emergency help immediately:

Symptoms of overdose:
  • Anxiety
  • blurred or loss of vision
  • change in consciousness
  • decrease in frequency of urination
  • decrease in urine volume
  • difficulty in passing urine (dribbling)
  • disturbed color perception
  • double vision
  • dry mouth
  • dry, flushed skin
  • fast, pounding, or irregular heartbeat or pulse
  • halos around lights
  • headache
  • hyperventilation
  • irritability
  • loss of consciousness
  • nervousness
  • night blindness
  • overbright appearance of lights
  • painful urination
  • pounding in the ears
  • seizures
  • shaking
  • sleepiness
  • trouble with sleeping
  • tunnel vision
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness

For Healthcare Professionals

Applies to scopolamine: compounding powder, injectable solution, oral tablet, transdermal film extended release


Cardiovascular side effects are limited when scopolamine (the active ingredient contained in Transderm-Scop) is delivered transdermally. Occasionally, there may be some clinically insignificant reductions in heart rate or blood pressure.[Ref]


Dermatologic side effects have included rash, dryness of the skin, and erythema. Dermatitis may occur at the site of application, in some cases due to the scopolamine (the active ingredient contained in Transderm-Scop) itself.[Ref]


Gastrointestinal side effects reported have included dry mouth, which occurred in approximately two-thirds of the patients using the transdermal patch.[Ref]


Most adverse effects of scopolamine (the active ingredient contained in Transderm-Scop) are extensions of its pharmacologic activity and are anticholinergic in nature. Scopolamine delivered transdermally is associated with considerably less side effects than when administered by other routes.[Ref]


Genitourinary side effects have included retention. Urinary retention has been reported infrequently with the transdermal patch.[Ref]

Nervous system

Nervous system side effects including drowsiness occurs quite frequently and is reported by about 17% of patients administered the scopolamine (the active ingredient contained in Transderm-Scop) transdermal patch. Other nervous system side effects are sporadic, including dizziness, restlessness, insomnia, disorientation, memory disturbances, hallucinations, paranoia, and confusion. Most reports of scopolamine-induced psychosis and delirium have involved the elderly, although some behavioral and mental irregularities may also be seen in young children. Concomitant use of antihistamines and other anticholinergics may be predisposing factors.

Recurrent migraine attacks have been described in one individual following an apparent scopolamine intoxication characterized by weakness, blurred vision, drowsiness, confusion, motor incoordination, and a stuporous state lasting 2 hours.[Ref]

Recurrent classic migraine attacks developed in a 20-year-old naval crew member who had been treated continuously with transdermal scopolamine for 5 months. The initial attack occurred within 24 hours of diagnosis of scopolamine intoxication. The patient had no self or family history of migraines. The attacks, presenting with prodrome and aura, followed by severe throbbing left headache, nausea, photophobia and sonophobia lasting 6 to 8 hours, recurred every 10 to 14 days for more than a year. Common triggers of migraines and other precipitating factors could not be identified in this case.[Ref]


Ocular side effects have included transient mydriasis and cycloplegia, resulting in blurred vision. Symptoms generally resolve within 2 days following removal of the patch but may take longer depending on the cumulative dose received. Unilateral dilation of the pupil and anisocoria have been reported, suggesting that some ocular events may be due to inadvertent contamination of the eye when there is failure to wash the hands after drug application. Narrow angle glaucoma resulting from bilateral mydriasis has been reported rarely but, in one case, required surgery. Esotropia has also occurred in a pediatric patient with neurodevelopmental disabilities but resolved several days after removal of the patch.[Ref]


Withdrawal symptoms may seldomly develop within 2 or 3 days following removal of the patch, usually in patients who have used it for more than 3 days. These symptoms are consistent with rebound cholinesterase activity and include dizziness, nausea, vomiting, paresthesias of the hands and feet, dysphoria, and hypotension.[Ref]


1. "Product Information. Scopace (scopolamine)." Hope Pharmaceuticals, Scottsdale, AZ.

2. Clissold SP, Heel RC "Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy." Drugs 29 (1985): 189-207

3. Gordon CR, Shupak A, Doweck I, Spitzer O "Allergic contact dermatitis caused by transdermal hyoscine." BMJ 298 (1989): 1220-1

4. Johnson P, Hansen D, Matarazzo D, Petterson L, Swisher C, Trappolini A "Transderm Scop for prevention of motion sickness." N Engl J Med 311 (1984): 468-9

5. "Multum Information Services, Inc. Expert Review Panel"

6. "Product Information. Transderm Scop (scopolamine)." Ciba Self-Medication Inc, Woodbridge, NJ.

7. Cairncross JG "Scopolamine psychosis revisited." Ann Neurol 13 (1983): 582

8. Wilkinson JA "Side effects of transdermal scopolamine." J Emerg Med 5 (1987): 389-92

9. Checketts MR, Coventry DM "Transdermal hyoscine and confusion in the elderly." Anaesthesia 47 (1992): 1097

10. Farley T "Check behind the ears." J Fam Pract 34 (1992): 676-7

11. Rozzini R, Inzoli M, Trabucchi M "Delirium from transdermal scopolamine in an elderly woman." JAMA 260 (1988): 478

12. Osterholm RK, Camoriano JK "Transdermal scopolamine psychosis." JAMA 247 (1982): 3081

13. Johnson SF, Moore RJ "Transderm pupil and confusion in a 10 year old." Ann Neurol 13 (1983): 583

14. Gordon CR, Mankuta D, Shupak A, Spitzer O, Doweck I "Recurrent classic migraine attacks following transdermal scopolamine intoxication." Headache 31 (1991): 172-4

15. Mego DM, Omori JM, Hanley JF "Transdermal scopolamine as a cause of transient psychosis in two elderly patients." South Med J 81 (1988): 394-5

16. Ziskind AA "Transdermal scopolamine-induced psychosis." Postgrad Med 84 (1988): 73-6

17. Rodysill KJ, Warren JB "Transdermal scopolamine and toxic psychosis." Ann Intern Med 98 (1983): 561

18. MacEwan GW, Remick RA, Noone JA "Psychosis due to transdermally administered scopolamine." Can Med Assoc J 133 (1985): 431-2

19. Rosenberg M "Preoperative anisocoria from a scopolamine patch." Anesth Analg 66 (1987): 693

20. Riddick FA Jr, Jordan JD "Cruise ship anisocoria." Ann Intern Med 117 (1992): 95

21. Verdier DD, Kennerdell JS "Fixed dilated pupil resulting from transdermal scopolamine." Am J Ophthalmol 93 (1982): 803-4

22. Fraunfelder FT "Transdermal scopolamine precipitating narrow-angle glaucoma." N Engl J Med 307 (1982): 1079

23. Hughes SS, Zaloga GP "Scopolamine anisocaria." Ann Emerg Med 18 (1989): 423-4

24. Thiele EA, Riviello JJ "Scopolamine patch-induced unilateral mydriasis." Pediatrics 96 (1995): 525

25. Good WV, Crain LS "Esotropia in a child treated with a scopolamine patch for drooling." Pediatrics 97 (1996): 126-7

26. Carlston JA "Unilateral dilated pupil from scopolamine disk." JAMA 248 (1982): 31

27. Bienia RA, Smith M, Pellegrino T "Scopolamine skin-disks and anisocoria." Ann Intern Med 99 (1983): 572-3

28. McCrary JA 3d, Webb NR "Anisocoria from scopolamine patches." JAMA 248 (1982): 353-4

29. Moser M "More on transderm scop patches." N Engl J Med 311 (1984): 1377

30. Steer RC "More on transderm scop patches." N Engl J Med 311 (1984): 1377-8

31. Saxena K, Saxena S "Scopolamine withdrawal syndrome." Postgrad Med 87 (1990): 63-6

It is possible that some side effects of Transderm-Scop may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.